Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Biogen Stock a Buy?

TheMotleyFool

0 0

Investors who bought shares of Biogen (NASDAQ: BIIB) in 2010 or earlier and held onto them have plenty of reason to smile; Biogen has gained more than 390% since 2010. Last year, its portfolio of more than 10 drugs, including partnered therapies, generated $13.5 billion in total revenue.

Investors who are newer to the Biogen story, though, might not be as happy. The stock is down 40% from the high it reached in March 2015, and it finished last year 1.4% lower after the company scrapped development of its Alzheimer's drug aducanumab, but then reinstated the program.

Image source: Getty Images.

Source Fool.com

Like: 0

BIIB

Share